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Deﬁciency of cartilage-associated protein (CRTAP) or prolyl 3-hydroxylase 1(P3H1) has been reported in autosomal-recessive lethal or
severe osteogenesis imperfecta (OI). CRTAP, P3H1, and cyclophilin B (CyPB) form an intracellular collagen-modifying complex that
3-hydroxylates proline at position 986 (P986) in the a1 chains of collagen type I. This 3-prolyl hydroxylation is decreased in patients
with CRTAP and P3H1 deﬁciency. It was suspected that mutations in the PPIB gene encoding CyPB would also cause OI with decreased
collagen 3-prolyl hydroxylation. To our knowledge we present the ﬁrst two families with recessive OI caused by PPIB gene mutations.
The clinical phenotype is compatible with OI Sillence type II-B/III as seen with COL1A1/2, CRTAP, and LEPRE1 mutations. The
percentage of 3-hydroxylated P986 residues in patients with PPIB mutations is decreased in comparison to normal, but it is higher
than in patients with CRTAP and LEPRE1 mutations. This result and the fact that CyPB is demonstrable independent of CRTAP and
P3H1, along with reported decreased 3-prolyl hydroxylation due to deﬁciency of CRTAP lacking the catalytic hydroxylation domain
and the known function of CyPB as a cis-trans isomerase, suggest that recessive OI is caused by a dysfunctional P3H1/CRTAP/CyPB
complex rather than by the lack of 3-prolyl hydroxylation of a single proline residue in the a1 chains of collagen type I.Collagen type I is the major protein component of the
extracellular matrix of bone and skin.1 It is a trimeric mole-
cule in which each chain consists of repeating Gly-X-Y
triplets in which proline and hydroxyproline (4Hyp)
usually occupy the X and Y positions, respectively.
Collagen type I is ﬁrst synthesized as procollagen type I,
consisting of two proa1(I) chains and one proa2(I) chain
containing N- and C-terminal propeptides.2 After correct
alignment of these three chains, propagation of triple
helical folding in the C-to-N direction occurs in the rough
endoplasmic reticulum (rER) in a zipper-like fashion3
during post-translational modiﬁcation by speciﬁc rER
proteins.2 In the literature, two important post-transla-
tional modiﬁcation systems of collagen type I are known:
(i) hydroxylation of multiple proline and lysine residues
by, respectively, prolyl 4-hydroxylase, providing the triple
helix with thermal stability, and lysyl-hydroxylase,
providing attachment sites for carbohydrate units as well
as stability of intermolecular cross links, and (ii) 3-hydrox-
ylation of a single residue, proline at position 986 (P986),
in the a1 chain by the rER protein complex consisting
of P3H1(MIM 610339), CRTAP (MIM 605497), and CyPB
(MIM 123841).1
Osteogenesis imperfecta (OI [MIM 166200, 166210,
259420, and 166220]) is an inherited connective-tissue
disorder characterized clinically by bone fragility andThe Amerincreased susceptibility to fractures. Autosomal-dominant
OI is usually caused by COL1A1 (MIM 120150) and
COL1A2 (MIM 120160) mutations that disturb the primary
structure of collagen type I and result in delayed triple
helical folding and post-translational overmodiﬁcation.
CRTAP4 and LEPRE15 mutations, encoding CRTAP and
P3H1, respectively, cause autosomal-recessive lethal or
severe OI characterized by decreased 3-prolyl hydroxyl-
ation of P986 in the a1 chain of collagen type I and
by post-translational overmodiﬁcation.1 The function of
3-hydroxyproline in the a1 chains of collagen type I is
not quite clear, but it has been hypothesized that 3-hy-
droxyproline takes part in protein-collagen interactions
required for bone formation.6 In vitro studies have shown
that P3H1 is responsible for prolyl 3-hydroxylase activity
because the presence of CRTAP and CyPB is not required
for full 3-prolyl hydroxylation activity.7 CRTAP and
P3H1 share the same N terminal domain, but CRTAP lacks
the catalytic-hydroxylation domain. Remarkably, CRTAP
mutations appear to cause decreased 3-prolyl hydroxyl-
ation as well. Therefore, it was hypothesized that deﬁ-
ciency in collagen 3-Hyp might simply be a marker for
the ‘‘dysfunctional’’ complex rather than an actual cause
of lethal or severe OI.8 Also, the role of the third member
CyPB in this 3-prolyl hydroxylation complex remained
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gene9 and is known to belong to the cyclophilins (Cyps),
a conserved class of intracellular and/or secreted proteins
originally identiﬁed as cellular binding proteins for
the immunosuppressive drug cyclosporin A (CsA).10 The
Cyps are a family of peptidyl-prolyl cis-trans isomerases
(PPIases), which catalyze the cis-trans isomerisation of
peptide bonds. CyPB has a signal sequence directing it
to the rER11, but it is also secreted extracellularly and
appears to play a role in inﬂammation, viral infection,
and cancer.10 Previous studies showed that CyPB directly
interacts with procollagen, which is necessary because
procollagen contains many cis-conformers. These have to
be converted to trans-conformers because only trans
peptide bonds can be incorporated into the triple collagen
helix.12 CyPB is also involved in procollagen export and
secretion along with HSP47, a collagen-binding heat-shock
protein.11 It was assumed that, because of coexistence in
the complex with P3H1 and CRTAP, a CyPB deﬁciency
would also result in decreased 3-prolyl hydroxylation,
post-translational overmodiﬁcation, and autosomal-reces-
sive OI,8 suggesting PPIB as an important candidate gene
for OI.13,14
Therefore, we performed sequence analysis of the PPIB
gene in four affected individuals from two families in
whom no COL1A1/2, CRTAP, or LEPRE1 mutations were
detected. The procedures followed were in accordance
with institutional and national standards on human
experimentation. Appropriate informed consent was
obtained from the families. Proband 1 from family 1
(P1-1) (Figure 1A) was delivered after termination of preg-
nancy at 22 weeks and 1 day of gestation. She was the
second child of nonconsanguineous North European
parents. During pregnancy, the diagnosis OI was suspected
on the basis of advanced ultrasounds. Radiographs and an
autopsy showed an absence of rib fractures and the pres-
ence of shortened, bowed, and fractured long bones
without evident rhizomelia, consistent with a diagnosis
of OI type II-B. Weight and head circumference were
normal for the gestational age, and no other abnormalities
were noted. Bone histology was indicative of OI. Overmo-
diﬁcation of collagen type I in ﬁbroblasts was evident on
electrophoresis.
Proband 2 from family 1 (P1-2) was delivered after termi-
nation of pregnancy at 16 weeks and 1 day of gestation
(Figure S1A). During pregnancy the diagnosis OI was
made on the basis of advanced ultrasounds and overmodi-
ﬁcation of collagen type I in chorionic villi cells. Radio-
graphs and autopsy showed osteopenia, no apparent rib
fractures, and short long bones with fractures but without
evident rhizomelia. Weight and head circumference were
normal for the gestational age, and no other abnormalities
were noted. The histology was indicative of OI. A diagnosis
of OI type II-B was made.
Proband 1 from family 2 (P2-1) (Figures S1B–S1H) was
delivered at 38 weeks of gestation by Caesarian section to
consanguineous Pakistani parents (ﬁrst cousins). Birth
weight was 2.89 kg (p25). Multiple long-bone fractures522 The American Journal of Human Genetics 85, 521–527, Octobehad been detected at 20 weeks gestation on an ultrasound
scan and were evident at birth. A large head with large
anterior fontanelle was noted in combination with gray
colored sclera typical of severe OI; ﬂexed and abducted
hips; and short, bowed femurs with anterior bowing of
the tibiae. Hypermobility of the joints, especially the hip
and ﬁnger joints, was seen. Based on clinical features and
X-ray ﬁndings, P2-1 was diagnosed with OI type III. Treat-
ment with 0.5 mg/kg/day intravenous Pamidronate for
3 days every 6 weeks was started at age 2 weeks. Gross
motor development was delayed; P2-1 achieved unsup-
ported sitting at age 2.5 years and standing with support
at age 4.5 years. No new fractures occurred between birth
and the age of 3 years. There were no signs of dentinogen-
esis imperfecta. Kyphoscoliosis of the thoracic and lumbar
spine was evident. P2-1 never walked, and at the age of
7 years P2-1 uses a wheelchair. Current height at the age
of 8 years is 79.9 cm (SDS 8.4), which is at the 50th
percentile for a 17-month-old child.
Proband 2 from family 2 (P2-2) (Figure 1B) was born by
elective Caesarian section at 37 weeks of gestation. On
an antenatal ultrasound scan at 20 weeks of gestation,
multiple fractures indicative of OI were observed. Birth
Figure 1. Radiological Features of Affected Probands from
Families 1 and 2
(A) Fetal anteroposterior radiographs of proband 1 from family 1 at
21þ 2 weeks of gestation show the following: normal skull miner-
alization for gestational age; slender ribs without fractures; incom-
pleteossiﬁcationofT5andT12; somewhat irregularproximalmeta-
physes of the humeri, radii, and ulnae; and bowing of the ulnae.
Bowed femorawith fractures and some loss ofmodeling andbowed
tibiae and ﬁbula, possibly with fractures, are apparent. The radio-
logical features are compatible with Sillence OI type II-B/III.
(B and C) Radiographs of proband 2 from family 2 show normal
mineralization of the skull, fractures of both humeri and radii
and the left ulna with callus formation and some loss of modeling
of the humeri. Discontinuously beaded ribs and a small, bell-
shaped thorax are noted. Multiple fractures with callus formation
of femora, tibiae, and ﬁbula exist with moderate loss of modeling
of the femora. The radiological features are compatible with Sil-
lence OI type II-B/III.r 9, 2009
weight was 2.32 kg (p10), and a skeletal survey conﬁrmed
multiple fractures of ribs and limbs. A large head with
a large anterior fontanelle was observed in combination
with some occipital ﬂattening. There was no chest defor-
mity. The legs were abducted at the hips in a frog-leg
position. Bowing of the femora and anterior bowing of
the tibae were noted. At the age of 6 months, her length
is 47.4 cm (SDS8.8). Treatment with 0.5mg/kg/day intra-
venous Pamidronate on 3 consecutive days every 8 weeks
commenced shortly after birth.
In Family 1, sequencing of the ﬁve exons of PPIB and
adjacent intronic sequences withM13 tailed primers (Table
S1) yielded a homozygous mutation c.556–559 delAAGA
in exon 5; this mutation resulted in p.Lys186GlnfsX8
(Figure 2A) in both affected siblings (P1-1 and P1-2). The
mutation leads to a frameshift that replaces 31 C-terminal
amino acids that are highly conserved in evolution, and it
is therefore expected to affect protein function. The
parents proved to be heterozygous carriers. In family 2,
we detected a homozygous mutation c.451 C > T in
exon 4 of the PPIB gene; this mutation resulted in
p.Gln151X (Figure 2B) in both affected siblings (P2-1 and
P2-2). The parents were heterozygous carriers. This muta-
tion removes the last 65 amino acids at the C-terminal.
Therefore, the mutation can lead either to diminished
protein function or to nonsense-mediated decay (NMD).
These PPIB mutations were not found in 192 alleles from
clinically normal controls. The homozygous mutation
Control
Parent
Patient
A B Figure 2. PPIB Mutations in Severe OI
(A) A homozygous c.556–559 delAAGA in
exon 5 resulting in p.Lys186GlnfsX8 is
shown in probands of family 1.
(B) A homozygous c.451 C> Tmutation in
exon 4 resulting in p.Gln151X is shown in
probands of family 2.
c.556–559 delAAGA in exon 5 leads
to a premature stop in the last exon,
and therefore NMD is unlikely to
occur. Quantitative RT-PCR (Lightcy-
cler480, Roche, Nutley, NJ, USA)
(Table S2) showed equal expression
of both wild-type and mutant PPIB
mRNA in the parents of P1-1 and P1-
2, indicating that no NMD occurs, as
was expected. The total mRNA level
of mutant and wild-type PPIB in ﬁbro-
blasts form the parents as well as the
level of mutant mRNA in P1-1 were
comparable to the level of wild-type
PPIB mRNA in healthy control ﬁbro-
blasts. Interestingly, intracellular
CyPB was detectable in ﬁbroblasts
from the control cell line and from
the father of P1-1 and P1-2 but was
undetectable in ﬁbroblasts from P1-1
(Figure 3), as measured by immunoblot with a monoclonal
CyPB antibody raised against the C-terminal tail
(HPA012720, Atlas Antibodies, Stockholm, Sweden) and
two different polyclonal antibodies raised against the
whole protein (11607-1-AP, Proteintech, Manchester,
United Kingdom and AF5410, R&D systems, Minneapolis,
MN, USA). The absence of truncated CyPB in the proband
P1-1 might be explained in one of the following ways: (i)
truncated protein is generated, but the amount is insufﬁ-
cient to be detected by immunoblot, or (ii) truncated
protein is rapidly degraded. To investigate the function of
CyPB in the complex and the interactions of CyPB with
P3H1 and CRTAP in complex assembly, we performed
immunohistochemistry as reported elsewhere15 with
CRTAP antibody (sc-100920, Santa Cruz, Santa Cruz, CA,
USA), P3H1 antibody (H00064175-B01P, Abnova, Taipei,
Taiwan) and the CyPB antibodies raised against the
C-terminal tail (HPA012720, Atlas Antibodies, Stockholm,
Sweden) and the whole CyPB protein (11607-1-AP, Pro-
teintech, Manchester, United Kingdom) on bone tissue
from P1-1 and P1-2 and from two probands with auto-
somal-recessive OI due to CRTAP and LEPRE1 mutations
(Figures 4A–4O). Interestingly, in bone tissue of patients
with CRTAP or LEPRE1 mutations, antibody staining was
observed for neither CRTAP nor P3H1 (4G-M), whereas
in P1-2 with PPIBmutations, no signal of CyPB was noted,
and a positive signal of CRTAP and P3H1 was identiﬁed
(4M-O). Apparently, the presence of both CRTAP andThe American Journal of Human Genetics 85, 521–527, October 9, 2009 523
P3H1 is needed for a stable protein complex, whereas CyPB
is demonstrably independent of the presence of either
CRTAP or P3H1. This has been demonstrated previously
(W. Chang et al., 2008, American Society for Bone and
Mineral Research, Abstract). Recently, it was reported that
the P3H1/CRTAP/CyPB complex has three distinct activi-
ties: it is a prolyl 3-hydroxylase, a PPIase, and a molecular
chaperone. Consequently, it was hypothesized that auto-
somal-recessive OI due to LEPRE1 and CRTAP mutations
resulted not only from a lack of 3-Hyp residues in the
collagen type I chains but also from a disturbance in the
additional function of the P3H1/CRTAP/CyPB complex
as a chaperone and PPIase.16 To further investigate this
hypothesis, we performed tandem mass spectrometry of
collagen tryptic peptides17 in individuals with OI due to
LEPRE1, CRTAP, COL1A1, and PPIB mutations (technical
details can be found in Figure S3). In P1-2, homozygous
for a PPIB mutation, the P986 3-hydroxylation level was
lower (33%) than control levels (93%–100%) but still
higher than that observed in patients with CRTAP (16%)
and LEPRE1 (22%) mutations (Figure 5). This result and
the fact that CyPB itself is stable and does not require the
presence of CRTAP or P3H1, as well as both reported
decreased 3-prolyl hydroxylation due to deﬁciency of
CRTAP4 lacking the catalytic hydroxylation domain and
the known function of CyPB, suggest that OI is caused
by a dysfunctional CRTAP/P3H1/CyPB complex rather
than by a lack of 3-hydroxylation of a single proline
residue in the a1 chains of collagen type I. Given the
above, PPIB mutations might also disrupt the folding of
the type I collagen helix as a result of interference with
PPIase activity and/or chaperone function, two other
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Figure 3. Immunoblot in Family 1
An immunoblot is shown of ﬁbroblast CyPB, which is lacking in
the affected infant P1-1 and present in the parent and the control
(polyclonal antibodies raised against the whole protein were used
in this immunoblot, 11607-1-AP, Proteintech, Manchester, UK).
CRTAP is present in P1-1, the parent, and the control.CRTAP AB 
staining
P3H1 AB    
staining
CyPB AB
staining
Patient without 
OI
Patient with OI 
due to COL1A1
mutation
Patient with OI 
due to CRTAP
mutations
Patient with OI 
due to LEPRE1
mutations
Patient with OI 
due to PPIB
mutations
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Figure 4. Results of Immunohistochem-
istry with Antibodies against CRTAP,
P3H1, and CyPB
Immunohistochemistry performed on
bone tissue with CyPB-CRTAP and P3H1
antibodies shows the following:
(A–C) a positive signal of CyPB, CRTAP,
and P3H1 in a control without OI;
(D–F) a positive signal of CyPB, CRTAP, and
P3H1 in a patient with a COL1A1mutation
(c.1238G > A [p.Gly413Asp]);
(G–I) no signal of either CRTAP or P3H1
but a signal of CyPB in a patient with a
homozygous c.404 delG CRTAP mutation;
(J–L) no signal of either P3H1 or CRTAP
and a signal of CyPB in a patient with
a homozygous c.401_402 delAA LEPRE1
mutation; and
(M–O) no signal of CyPB but signals of
both CRTAP and P3H1 antibodies in P1-2
with a homozygous PPIB mutation.
AB: antibody.524 The American Journal of Human Genetics 85, 521–527, October 9, 2009
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Figure 6. Electrophoresis of Collagen Type I Chains in Fibroblasts and Chorionic Villi of Patients with a Homozygous CRTAP, LEPRE1,
or PPIB Mutation or a Heterozygous COL1A1 Mutation
Backstreaking and/or increased band width is visible in cells (c) and media (m), indicating overmodiﬁcation of collagen type I chains in
chorionic villi cells and ﬁbroblasts of patients with lethal or severe OI due to homozygous CRTAP (p.Ala8fs), LEPRE1 (p.Glu134fs), or
PPIB (p.Lys186GlnfsX8) mutations or a heterozygous COL1A1 (p.G965S in chorionic villi cells and p.G662V in ﬁbroblasts) mutation.
The slight apparent overmodiﬁcation of other collagens appears to be an effect typically evident in chorionic villi.recently reported functions of the P3H1/CRTAP/CyPB
complex. Further investigations will need to shed more
light on this. It is already known that inhibition of CyPB
in cultured dermal ﬁbroblasts with cyclosporine A
increases modiﬁcation of the type I collagen chains, which
indicates that overmodiﬁcation of collagen type I in auto-
somal-recessive OI due to PPIB mutations results from
a decreased rate of cis-trans isomerization by CyPB.18
Collagen type I electrophoresis performed as reported else-
where19 showed overmodiﬁcation of collagen type I chains
comparable to collagen type I overmodiﬁcation observed
in patients with CRTAP and LEPRE1 mutations and in
patients with COL1A1 mutations causing lethal or severe
OI (Figure 6). In conclusion, we describe mutations in
the PPIB gene encoding the third member, CyPB, of the
collagen-modifying complex. PPIB mutations result in
autosomal-recessive OI with a clinical picture compatible
with OI type II-B/III, as is the case with CRTAP4,13,20 and
LEPRE15,13 mutations. Our ﬁndings, in combination with
recent literature, support the hypothesis that OI due to
PPIB mutations results from a disruption of the function526 The American Journal of Human Genetics 85, 521–527, Octobeof the P3H1/CRTAP/CyPB complex as a prolyl 3-hydroxy-
lase, a PPIase, and a molecular chaperone.16
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Figure 5 shows mass spectrometry analysis of the C1A1 P986-containing tryptic peptide, modiﬁed with either two or three hydroxyl
groups (as indicated by an asterisk below the modiﬁed proline residue in Figure S2) in patients with homozygous PPIB (A), LEPRE1
(B), or CRTAP (C) mutations or a heterozygous COL1A1 mutation (D), in the parents of the patient with PPIB mutations (E and F),
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panel shows the corresponding summedmass spectra (40–50 min.). XIC peak areas were determined for doubly and triply hydroxylated
peptides. The C1A1 P986 3-hydroxylation level (%) was calculated as triple-hydroxylation area (triple-hydroxylation area þ double-
hydroxylation area). Collagen I a-1 peptides that show normal P986 3-hydroxylation have an m/z ratio of 781.4, whereas peptides lack-
ing 3-hydroxylation have an m/z ratio of 773.4. Controls (D–F) show normal 3-hydroxylation (>90%). P1-1 with homozygous PPIB
mutations (A) shows decreased 3-hydroxylation (33%). Patients with homozygous LEPRE1 (p.Glu134fs) or CRTAP (p.Ala8fs) mutations
(B and C, respectively), however, show even more decreased 3-hydroxylation levels (22% and 16%, respectively).r 9, 2009
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Note Added in Proof
This version of this paper differs from that originally pub-
lished online in that an Accession Numbers section has
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